Fresenius Kabi Canada announces that its tocilizumab biosimilar Tyenne® referencing Actemra®** (tocilizumab) is now commercially available in Canada. Tyenne® is the first and only tocilizumab ...

WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) ...

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful ...

The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically ...